ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE

Urszula Chmielowiec ,  Jerzy Winiarski ,  Teresa Paszkowska-Reymer ,  Wioleta Maruszak 

Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland

Abstract

Multistep synthesis of 4-[2-(dipropylamino)-etyhl]-1,3-dihydro-2H-indol-2-one hydrochloride (ropinirole hydrochloride) was elaborated in Pharmaceutical Research Institute. From ten steps of synthesis - reduction of starting 2-methyl-3-nitrobenzoic acid to the corresponding alcohol, reaction of chain extension and reductive cyclization to indolone ring play significant role in the process of the formation find product.

mknolrop5.JPG

Development of synthetic steps one to four was based on the literature data [1] and steps five to ten were carried out according to the patent procedure [2].

References

1. Bhaskar Kanth J.V., Periasamy M., J. Org. Chem. 1991, 56, 5964-5965.

2. Patent EP 113964 (1982).

Legal notice
  • Legal notice:

    Copyright (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/7169 must be provided.

 

Related papers
  1. Improved manufacturing process of bosentan monohydrate.
  2. Evaluation of potential genotoxic impurities in prasugrel intermediate by HPLC chromatography
  3. Simultaneous CE determination of counterion and possible impurity from synthetic route in pharmaceutical substance prasugrel hydrochloride.
  4. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
  5. A novel synthesis of 19-nor analogs of vitamin D
  6. The Concept of the Central Strategic Program - Innovative Medicines
  7. New rosiglitazone salts
  8. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
  9. Polimorphism of Active Pharmaceutical Ingredients
  10. CAN A QUEST FOR A NEW DRUG OF POLISH ORIGIN BE SUCCESSFUL?
  11. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  12. SYNTHESIS OF PIOGLITAZONE HYDROCHLORIDE OF PHARMACEUTICAL PURITY AT SMALL PLANT SCALE
  13. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC®) SYNTHESIS.
  14. SYNTHESIS OF 25- HYDROXYVITAMIN D3 - CALCIFEDIOL FROM VITAMIN D2
  15. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.
  16. THE COMPARISON OF TWO VALIDATED HPLC METHODS FOR THE DETERMINATION OF (+)-CLOPIDOGREL HYDROGENSULFATE PURITY WITH THE USP METHOD.

Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Urszula Chmielowiec
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2006-04-07 10:34
Revised:   2009-06-07 00:44
Google
 
Web science24.com
© 1998-2021 pielaszek research, all rights reserved Powered by the Conference Engine